Articles by Shambavi Richard, MD
The mandate could affect moving CAR-T therapies into earlier lines of therapy for multiple myeloma.
The scales are shifting in the STEM fields as more women step into positions of responsibility, leadership, and influence.
In June 2023, a patient death led to the US Food and Drug Administration pausing the iMMagine-1 study.
The panelists highlight key data presented at ASCO 2023.
Toxicities such as cytokine release syndrome as they relate to BCMA bispecific antibodies for myeloma are discussed.
The panel discusses the new and emerging bispecific antibody treatment options for multiple myeloma.
The panel discusses data on the BCMA CAR-T construct PHE885 and the manufacturing needs that persist.
The panel discusses the real-world data and first-hand experience with the two FDA-approved CAR T-cell therapies for MM.
The panelists discuss their experience with CAR-T access challenges in the real-world clinical setting.
The panel discusses the FDA-approved BCMA-directed CAR-T options for multiple myeloma.
The panel discusses maintenance therapy options for early-relapsed multiple myeloma.
The panel considers triplet versus quadruplet therapy for myeloma induction.
The panel advises on patient hand off to local care teams following CAR T-cell therapy for myeloma.
The panel discusses side effect management with CAR T-cell therapy.
The panel addresses the choice between treating multiple myeloma with a bispecific agent or CAR T-cell therapy.
Drs. Martin and Voorhees discuss patient characteristics and populations that are suited for CAR-T therapy in myeloma.
The panel addresses the potential for frontline CAR-T use.
The panel debates whether CAR-T can be moved earlier in the course of myeloma treatment.
The panel discusses allogeneic CAR T-cell therapy and how it stacks up against autologous options.
Drs. Lonial and Martin discuss allogeneic, off-the-shelf CAR-T data.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.